Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Efficacy and Safety of Precision Therapy in Refractory Tumor
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Baodong Qin
- Target Recruit Count
- 300
- Registration Number
- NCT03239015
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 128
- Registration Number
- NCT03126799
- Locations
- 🇰🇷
National Cancer Center, Goyang-Si, Gyeonggi-do, Korea, Republic of
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT03110484
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
- Conditions
- Interventions
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03076164
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Io Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT02991651
- Locations
- 🇺🇸
Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT02961374
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇵🇷University of Puerto Rico, San Juan, Puerto Rico
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Study of Ixazomib and Erlotinib in Solid Tumors
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02942095
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02886195
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2019-04-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT02775006
- Locations
- 🇳🇱
VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇳🇱Laurentius Hospital, Roermond, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.